Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:The role of antibody-drug conjugates in the treatment of lung cancer
Authors:ID Zlatanova, Tanya (Author)
ID Changalova, Aynura (Author)
ID Janžič, Urška, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author)
Files:URL URL - Source URL, visit https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1757564/full
 
.pdf PDF - Presentation file, download (1,73 MB)
MD5: 89294717696C65E25AAE4B6C1018ED62
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Over the last decades, lung cancer treatment has improved immensely, mainly due to the incorporation of new targeted treatments and immunotherapy. A relatively new and potentially highly effective class of drugs, antibody-drug conjugates (ADCs), has been introduced to the clinical setting and is currently under intense investigation, alone and in combination with other molecules. This study aims to summarize the latest data on ADCs for lung cancer treatment and to analyze their potential, toxicity profile, and challenges.
Keywords:ADC, antibody-drug conjugate, non-small cell lung cancer, small-cell lung cancer, targeted therapy, immunotherapy
Publication status:Published
Publication version:Version of Record
Submitted for review:30.11.2025
Article acceptance date:22.01.2026
Publication date:05.02.2026
Publisher:Frontiers Editorial Office, 2011-
Year of publishing:2026
Number of pages:18 str.
Numbering:Vol. 16, article no. ǂ1757564
Source:Frontiers in oncology
PID:20.500.12556/DiRROS-27400 New window
UDC:616.24-006:615.277
ISSN on article:2234-943X
DOI:10.3389/fonc.2026.1757564 New window
COBISS.SI-ID:267418115 New window
Copyright:© 2026 Zlatanova, Changalova and Janzic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Note:Nasl. z nasl. zaslona; Vse avtorice so k temu delu prispevale enakovredno; Soavtorica iz Slovenije: Urška Janžič; Opis vira z dne 5. 2. 2026;
Publication date in DiRROS:05.02.2026
Views:555
Downloads:185
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Frontiers in oncology
Shortened title:Front. oncol.
Publisher:Frontiers Editorial Office
ISSN:2234-943X
COBISS.SI-ID:1601583 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:05.02.2026

Secondary language

Language:Slovenian
Keywords:konjugati protitelo-zdravilo, nedrobnocelični pljučni rak, drobnocelični pljučni rak, tarčno zdravljenje, imunoterapija


Back